Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with
or without atezolizumab works in treating patients with breast cancer that has spread to
other parts of the body (metastatic). Chemotherapy drugs, such as paclitaxel, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted
therapy" because it works by attaching itself to specific molecules (receptors) on the
surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2
receptors, the signals that tell the cells to grow are blocked and the cancer cell may be
marked for destruction by the body's immune system. Monoclonal antibodies, such as
pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy
with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system
and may interfere with the ability of tumor cells to grow and spread. It is not yet known
whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill
more tumor cells.